This is a StreetInsider.com Premium Only Page

(MNPR) – StreetInsider.com Reports

Apr 16, 2024 08:13 AM Monopar Therapeutics (MNPR) Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Apr 11, 2024 07:16 AM Jones Trading Upgrades Monopar Therapeutics (MNPR) to Buy on latest MNPR101 data

Apr 10, 2024 08:03 AM Monopar Therapeutics (MNPR) Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Mar 5, 2024 07:00 AM Monopar Therapeutics (MNPR) Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Feb 22, 2024 07:01 AM Monopar Therapeutics (MNPR) Reports Preclinical Data for MNPR-101

Feb 20, 2024 08:00 AM Monopar Therapeutics (MNPR) Cleared to Proceed with First-in-Human Phase 1 Trial of MNPR-101-Zr

Nov 1, 2023 07:02 AM Monopar Therapeutics (MNPR) Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b

Aug 10, 2023 11:49 AM Jones Trading Downgrades Monopar Therapeutics (MNPR) to Hold

Jul 11, 2023 07:02 AM Monopar Therapeutics (MNPR) Announces MNPR-101 Radiopharma Collaboration Agreement with CSI Singapore

Jun 1, 2023 07:00 AM Monopar Therapeutics (MNPR) Reports Encouraging Camsirubicin Phase 1b Trial Update

May 15, 2023 06:38 AM Monopar Therapeutics (MNPR) PT Lowered to $2 at H.C. Wainwright

Mar 29, 2023 07:40 AM Maxim Group Downgrades Monopar Therapeutics (MNPR) to Hold

Mar 28, 2023 04:32 PM U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.12%

Mar 28, 2023 07:08 AM Monopar Therapeutics (MNPR) PT Lowered to $17 at EF Hutton

Mar 28, 2023 03:58 AM Monopar Therapeutics (MNPR) PT Lowered to $3 at Roth/MKM

Mar 27, 2023 05:02 PM Monopar Therapeutics (MNPR) Phase 2b/3 VOICE Trial of Validive Did Not Meet the Pre-Defined Threshold for Efficacy

Mar 27, 2023 04:55 PM Monopar Therapeutics (MNPR) Halted, News Pending

Mar 23, 2023 09:25 AM Monopar Therapeutics Inc. (MNPR) Misses Q4 EPS by 1c

Feb 27, 2023 07:03 AM Monopar Therapeutics (MNPR) and NorthStar Announce Expanded Radiopharma Program, Report Positive Preclinical Results

Jan 23, 2023 07:07 AM EF Hutton Starts Monopar Therapeutics (MNPR) at Buy

Jan 18, 2023 07:00 AM Monopar Therapeutics (MNPR) Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort

Dec 22, 2022 05:31 AM Monopar Therapeutics (MNPR) Announces Up to $100M Share Offering

Dec 12, 2022 07:09 AM Monopar Therapeutics (MNPR) Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Dec 9, 2022 07:37 AM Roth Capital Resumes Monopar Therapeutics (MNPR) at Buy

Nov 16, 2022 07:01 AM Monopar Therapeutics (MNPR) Reports Strong Clinical Data from Ongoing Camsirubicin Phase 1b Trial

Aug 11, 2022 09:29 AM Monopar Therapeutics (MNPR) PT Lowered to $18 at Roth Capital

Feb 15, 2022 08:05 AM Monopar Therapeutics (MNPR) Issues Update on Clinical and Preclinical Programs

Dec 8, 2021 08:07 AM Monopar Therapeutics (MNPR) Advances Dosing of Camsirubicin to Highest Levels

Nov 1, 2021 06:32 AM UPDATE: H.C. Wainwright Starts Monopar Therapeutics (MNPR) at Buy

Aug 3, 2021 08:12 AM Monopar Therapeutics (MNPR) Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

Jul 12, 2021 08:10 AM Monopar Therapeutics (MNPR) Appoints Octávio Costa, MD, as Chief Medical Officer

Jun 24, 2021 08:03 AM Monopar Therapeutics (MNPR) to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Jun 3, 2021 08:00 AM Monopar Therapeutics (MNPR) Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

Jun 1, 2021 04:12 PM Monopar Therapeutics (MNPR) Appoints Andrew Cittadine as its COO

May 26, 2021 08:07 AM Monopar Therapeutics (MNPR) and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic

May 24, 2021 08:09 AM Monopar Therapeutics (MNPR) and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

Mar 30, 2021 07:38 AM Monopar Therapeutics' (MNPR) uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

Mar 2, 2021 07:38 AM Monopar Therapeutics (MNPR) Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery

Feb 11, 2021 09:31 AM Monopar Therapeutics (MNPR) Halted on LUDP

Feb 11, 2021 07:40 AM Monopar Therapeutics (MNPR) Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

Feb 9, 2021 07:12 AM Monopar Therapeutics (MNPR) Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

Jan 28, 2021 07:30 AM Monopar Therapeutics (MNPR) Spikes 200%

Jan 28, 2021 06:07 AM UPDATE: Roth Capital Starts Monopar Therapeutics (MNPR) at Buy

Dec 22, 2020 08:32 AM Monopar Therapeutics (MNPR) Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

Dec 10, 2020 08:36 AM Monopar Therapeutics (MNPR) and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19

Dec 8, 2020 11:45 AM Monopar Therapeutics (MNPR) PT Lowered to $40 at Brookline Capital Markets, Following Clinical Trial Update, Model Update

Nov 9, 2020 08:34 AM Monopar Therapeutics (MNPR) Announces New Patents for Validive

Sep 24, 2020 07:41 AM Maxim Group Starts Monopar Therapeutics (MNPR) at Buy

Aug 19, 2020 08:34 AM Monopar Therapeutics (MNPR), NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

Aug 12, 2020 08:34 AM Monopar Therapeutics (MNPR) to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology